Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Biol Med (Maywood) ; 231(8): 1373-8, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16946406

RESUMEN

The enzyme dipeptidyl peptidase-IV (DPP-IV) inactivates a variety of bioactive peptides, including glucagon-like peptide-1 (GLP-1) and growth hormone releasing hormone (GHRH). Inhibiting DPP-IV in order to increase circulating GLP-1 is of interest as a treatment for Type II diabetes. Inactivation of DPP-IV may also increase circulating GHRH, potentially enhancing growth in domestic animals. To test the hypothesis that inhibition of DPP-IV activity will influence the growth hormone/ IGF-1 axis, growing pigs (Sus scrofa domesticus, 78 kg) were treated with a DPP-IV inhibitor (Compound 1, the 2,5-difluor-ophenyl analog of the triazolopiperazine MK0431, sitagliptin), and plasma concentrations of IGF-1 were monitored. Pigs were administered either sterile saline (0.11 ml/kg followed by a continuous infusion at 2 ml/hr for 72 hrs, controls, n = 2), Compound 1 (2.78 mg/kg followed by a continuous infusion at 0.327 mg/kg x hr for 72 hrs, n = 4) or GHRH (0.11 ml/kg sterile saline, followed by a continuous infusion of GHRH at 2.5 microg/ kg x hr for 48 hrs, n = 4). Plasma concentrations of Compound 1 were maintained at 1 microM, which resulted in a 90% inhibition of circulating DPP-IV activity. Relative to the predose 24-hr period, area under the IGF-1 concentration curve (AUC) tended to be lower (P = 0.062) with Compound 1 (.79 +/- 130 ng/ml x hr) than controls (543 +/- 330 ng/ml x hr). GHRH treatment increased the IGF-1 AUC (1210 +/- 160 ng/ml x hr, P = 0.049 vs. controls and P = 0.001 vs. Compound 1). We conclude that inhibition of DPP-IV does not alter the circulating levels of IGF-1 in the growing pig.


Asunto(s)
Catepsina C/antagonistas & inhibidores , Hormona Liberadora de Hormona del Crecimiento/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Animales , Área Bajo la Curva , Catepsina C/sangre , Catepsina C/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Hormona Liberadora de Hormona del Crecimiento/efectos de los fármacos , Factor I del Crecimiento Similar a la Insulina/efectos de los fármacos , Masculino , Pirazinas/farmacología , Fosfato de Sitagliptina , Porcinos , Triazoles/farmacología
2.
J Dent Res ; 90(4): 489-94, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21118795

RESUMEN

Fluorosed enamel can be porous, mottled, discolored, hypomineralized, and protein-rich if the enamel matrix is not completely removed. Proteolytic processing by matrix metalloproteinase-20 (MMP20) and kallikrein-4 (KLK4) is critical for enamel formation, and homozygous mutation of either protease results in hypomineralized, protein-rich enamel. Herein, we demonstrate that the lysosomal proteinase cathepsin K is expressed in the enamel organ in a developmentally defined manner that suggests a role for cathepsin K in degrading re-absorbed enamel matrix proteins. We therefore asked if fluoride directly inhibits the activity of MMP20, KLK4, dipeptidyl peptidase I (DPPI) (an in vitro activator of KLK4), or cathepsin K. Enzyme kinetics were studied with quenched fluorescent peptides with purified enzyme in the presence of 0-10 mM NaF, and data were fit to Michaelis-Menten curves. Increasing concentrations of known inhibitors showed decreases in enzyme activity. However, concentrations of up to 10 mM NaF had no effect on KLK4, MMP20, DPPI, or cathepsin K activity. Our results show that fluoride does not directly inhibit enamel proteolytic activity.


Asunto(s)
Proteínas del Esmalte Dental/efectos de los fármacos , Esmalte Dental/enzimología , Fluoruros/farmacología , Péptido Hidrolasas/efectos de los fármacos , Ameloblastos/efectos de los fármacos , Amelogénesis/efectos de los fármacos , Amelogénesis/fisiología , Animales , Catepsina C/análisis , Catepsina C/efectos de los fármacos , Catepsina K/antagonistas & inhibidores , Catepsina K/efectos de los fármacos , Inhibidores de Cisteína Proteinasa/farmacología , Dipéptidos/administración & dosificación , Dipéptidos/farmacología , Relación Dosis-Respuesta a Droga , Órgano del Esmalte/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Calicreínas/antagonistas & inhibidores , Calicreínas/efectos de los fármacos , Leucina/análogos & derivados , Leucina/farmacología , Metaloproteinasa 20 de la Matriz/efectos de los fármacos , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores de Proteasas/administración & dosificación , Inhibidores de Proteasas/farmacología , Inhibidores de Serina Proteinasa/administración & dosificación , Inhibidores de Serina Proteinasa/farmacología , Sulfonas/administración & dosificación , Sulfonas/farmacología , Porcinos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA